Ann: Imugene Receives A$20 million for Convertible Notes Issuance, page-187

Looks like very controlled accumulation to me on low volume. There was some toxicity concerns around Azer-Cel which IMU also encountered in Cohort A before they combined it with a small dose of IL-2 for Cohort B. Also, a major point of the purchase of Azer-Cel factored around the funding of the manufacturing plant which others suitors probably didn't want to make the commitment, the purchase of the acquisition of Azer-Cel was for CD19 required for the OASIS clinical trial to target "target-less" solid tumour which are very difficult to or have no current treat. Weren't you initially impressed with CHM's previous CEO who introduced LC to Azer-Cel so why has Azer-Cel changed your opinion especially after the clinical trial update was excellent for Cohort B????

And who know, maybe the other cancer which are deem less "target-less" also require CD19 to make CF33 more effective which is why IMU is conducting both VAXINIA and OASIS clinical trials in parallel. IMU doesn't need "mind blowing" announcement, they just need to show further positive clinical trial updates to demonstrate safety and the efficacy already shown in Ph1 clinical trial to advance to Ph2. This will further de-risk stock and don't forget, these IP are replacing the current SoC as the patients need to have failed multiple SoC to be on the clinical trials. Also, there hasn't been dose escalation for a while so I say IMU has determined the OBD need for Ph2/3 clinical trial which they've mentioned end of 2025. Like LC and YF said 3-4 months ago, the clinical trials are going as expected.